Log in to search using one of your social media accounts:

 

Pioglitazone, Sulfonylureas Safe and Effective in Type 2 Diabetes Pioglitazone, Sulfonylureas Safe and Effective in Type 2 Diabetes
They may not boast a cardiovascular benefit like other newer drugs, but these drugs can safely be added to metformin to manage type 2 diabetes.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 29, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

Pioglitazone Improves Left Ventricular Diastolic Function
Both whole - body and myocardial insulin sensitivity improved in type 2 diabetes patients (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 29, 2017 Category: Respiratory Medicine Tags: Cardiology, Endocrinology, Family Medicine, Internal Medicine, Nursing, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news

IRIS: Best Candidates for Pioglitazone After Stroke IRIS: Best Candidates for Pioglitazone After Stroke
Stroke patients with insulin resistance who are at greatest risk for repeat stroke derive the greatest benefit from pioglitazone treatment.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Sulfonylureas, Pioglitazone Similarly Safe for Add-On Therapy in Type 2 Diabetes (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD For patients with type 2 diabetes inadequately controlled with metformin, add-on treatment with either a sulfonylurea or pioglitazone seems similarly safe over the long-term, according to an open-label, multicenter study in … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 14, 2017 Category: Primary Care Source Type: news

For Metformin Add-On, No Winner in Head-to-Head CVD Trial (CME/CE)
(MedPage Today) -- Pioglitazone largely similar to sulfonylurea in pragmatic TOSCA.IT trial (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - September 13, 2017 Category: Urology & Nephrology Source Type: news

' Vote of Confidence for Sulfonylureas and Pioglitazone' in TOSCA IT'Vote of Confidence for Sulfonylureas and Pioglitazone' in TOSCA IT
"My bottom line is this is a vote of confidence for sulfonylureas and pioglitazone," said one expert."You could use these data to perhaps finesse which patients you might give them to."Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Another Study Ties Pioglitazone to Bladder Cancer Risk (CME/CE)
(MedPage Today) -- Risk emerged within first 2 years; attenuated after discontinuing (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - August 10, 2017 Category: Pediatrics Source Type: news

FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer
[6-15-2011] The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 1, 2017 Category: Drugs & Pharmacology Source Type: news

Actos (Pioglitazone Hydrochloride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 28, 2017 Category: Drugs & Pharmacology Source Type: news

ADA 2017: Evaluating Cardiovascular Safety of Antidiabetic Agents
Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017. (Source: ConsultantLive)
Source: ConsultantLive - June 14, 2017 Category: Internal Medicine Authors: Kenneth J. Bender, PharmD, MA Tags: Conferences/ADA 2017 Diabetes Diabetes Type 2 Source Type: news

Your NEJM Group Today: Pediatrics Board Review Questions / Pioglitazone & Fracture Risk / Missouri Infectious Disease Opportunity (FREE)
By the Editors Here's today's offering from NEJM Group:NEJM Knowledge+ Blog: To create the questions for NEJM Knowledge+ Pediatrics Board Review, the Knowledge+ team recruited authors from … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 30, 2017 Category: Primary Care Source Type: news

Pioglitazone May Improve NASH Histology for Many Patients Pioglitazone May Improve NASH Histology for Many Patients
Pioglitazone improved liver histology in patients with nonalcoholic steatohepatitis, even in the absence of diabetes, a meta-analysis has found.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 27, 2017 Category: Endocrinology Tags: Gastroenterology News Source Type: news

Revisiting the Use of Pioglitazone in the Treatment of T2D Revisiting the Use of Pioglitazone in the Treatment of T2D
Is it time to reconsider the role of pioglitazone in the management of type 2 diabetes?Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Exenatide-Pioglitazone Combo Tops Insulin in Type 2 Diabetes Exenatide-Pioglitazone Combo Tops Insulin in Type 2 Diabetes
The combination lowers HbA1c more effectively with less weight gain and hypoglycemia in type 2 diabetes patients poorly controlled on metformin plus a sulfonylurea in the Qatar study.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 17, 2017 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

FDA Warns of Bladder Cancer Risk From Diabetes Drug
The FDA has concluded that pioglitazone, used to treat type 2 diabetes, may be linked to an increased risk of bladder cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers News Practice & Policy Source Type: news

Adding Pioglitazone Could Improve Molecular Response in CML Patients
A small preliminary study showed that adding pioglitazone to imatinib therapy might have a favorable impact on residual disease in chronic myeloid leukemia, as measured by conversion to molecular response 4.5. (Source: CancerNetwork)
Source: CancerNetwork - January 5, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news

Actoplus MET, Actoplus MET XR (Pioglitazone Hcl and Metformin Hcl) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 28, 2016 Category: Drugs & Pharmacology Source Type: news

Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial - Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, Gorman M, Kelly MA, Lovejoy AM, Kernan WN.
CONTEXT: Pioglitazone reduces cardiovascular risk in non-diabetic patients after an ischemic stroke or transient ischemic attack (TIA) but is associated with increased risk for bone fracture. OBJECTIVE: To characterize fractures associated with pio... (Source: SafetyLit)
Source: SafetyLit - December 17, 2016 Category: Global & Universal Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

FDA Adds Bladder Cancer Warnings to Takeda's Actos
The U.S. FDA has concluded that use of Takeda's Actos (pioglitazone), a type 2 diabetes medicine, may be linked to an increased risk of bladder cancer and has approved label updates. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 14, 2016 Category: Pharmaceuticals Source Type: news

FDA Affirms Pioglitazone May Be Tied to Higher Bladder Cancer Risk (FREE)
By Kristin J. Kelley Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The type 2 diabetes drug pioglitazone may pose an increased risk for bladder cancer, the FDA … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 13, 2016 Category: Primary Care Source Type: news

FDA Still Sees Bladder Cancer Risk With Pioglitazone FDA Still Sees Bladder Cancer Risk With Pioglitazone
The agency reviewed new and conflicting research on the possible cancer risk of the diabetes drug and came down again on the side of risk.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 13, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Affirms Bladder Cancer Warning for Pioglitazone
(MedPage Today) -- Agency unpersuaded by manufacturer-sponsored study asserting no risk (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - December 12, 2016 Category: Endocrinology Source Type: news

FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer
[12-12-2016] As a result of an updated review, the U.S. Food and Drug Administration (FDA) has concluded that use of the type 2 diabetes medicine pioglitazone (Actos, Actoplus Met, Actoplus Met XR, Duetact, Oseni) may be linked to an increased risk of bladder cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 12, 2016 Category: Drugs & Pharmacology Source Type: news

Some drugs, banned in other countries, allowed in India: Government
Minister of State for Health Faggan Singh Kulaste in a written reply said that the drugs which have been allowed are nimesulide, analgin and pioglitazone. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 25, 2016 Category: Pharmaceuticals Source Type: news

Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news

Actos (pioglitazone)
Title: Actos (pioglitazone)Category: MedicationsCreated: 11/28/1999 12:00:00 AMLast Editorial Review: 9/20/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - September 20, 2016 Category: Endocrinology Source Type: news

3 Drugs with the Most Severe Side Effects
Image Source Drugs have been known to have some sort of side effects on patients. Most of them are not often discussed in the health tabloids. While other drugs have side effects that are very nominal when compared to the benefits the patient derives from their usage, others have side effects that can impact the lives of their users forever. The most common side effects people experience from drug usage are gastrointestinal related issues which include constipation, nausea, and vomiting. Some other drugs can leave you feeling tired and dizzy for a short period of time. Combining these drugs with simple aspirin will usuall...
Source: Healthy Living - The Huffington Post - August 19, 2016 Category: Consumer Health News Source Type: news

Pioglitazone Diabetes Prevention Data Now Published Pioglitazone Diabetes Prevention Data Now Published
Reductions in both cardiovascular events and progression to diabetes suggest that a reexamination of pioglitazone's risk/benefit profile may be in order.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 12, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Pioglitazone Improves Fatty Liver in Prediabetes, Diabetes Pioglitazone Improves Fatty Liver in Prediabetes, Diabetes
Results of a single-center randomized trial suggest the drug may halt NASH progression and alter the natural history of the disease. Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 5, 2016 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Pioglitazone effective in diabetes patients with NASH
Pioglitazone may halt the progression of nonalcoholic steatohepatitis in patients with prediabetes or Type 2 diabetes, a randomised trial shows. (Source: MedWire News)
Source: MedWire News - June 27, 2016 Category: Consumer Health News Tags: Diabetes Source Type: news

Long-Term Pioglitazone Use Effective in Patients with NASH and Prediabetes or Diabetes (FREE)
By Atif Zaman, MD, MPH Dr. Zaman is an associate editor with NEJM Journal Watch Gastroenterology, from which this story was adapted. Full coverage is available to subscribers at the link below.Pioglitazone is associated with improved disease activity in patients with nonalcoholic steatohepatitis (NASH) plus prediabetes or … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 20, 2016 Category: Primary Care Source Type: news

Pioglitazone safe and effective for steatohepatitis in T2DM
Long-term pioglitazone is not only safe for patients with nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes but is associated with significant improvements in fatty liver disease... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - June 20, 2016 Category: Endocrinology Source Type: news

Pioglitazone Slows Progression to Type 2 Diabetes: More IRIS DataPioglitazone Slows Progression to Type 2 Diabetes: More IRIS Data
New and previously reported data from the IRIS trial prompt discussion of reevaluating the role of now-generic pioglitazone in the treatment and prevention of diabetes and stroke. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 17, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Actos After Stroke May Prevent Diabetes (CME/CE)
(MedPage Today) -- Treatment appears to stop progression from pre-diabetes (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 15, 2016 Category: Cardiology Source Type: news

FDA Follies, Part 2
Part 1 of this series appeared just over a year ago (in a different publication), and detailed a few of the agency's recent missteps. Prominently mentioned was the sad case of certain diabetes meds, including Actos, once touted as a safer alternative to Avandia. Avandia was taken off the market in 2011, but reappeared subject to severe limitations of use. These limitations were later removed—although current usage of the drug is small. Oddly, Actos (FDA approved in July, 1999) was showing some problems (bladder cancer) as early as 2005, even though this information was not widely disseminated at the time. Some migh...
Source: Healthy Living - The Huffington Post - May 17, 2016 Category: Consumer Health News Source Type: news

Is the Diabetes 'Holy Grail' in Reach?Is the Diabetes 'Holy Grail' in Reach?
With empagliflozin, pioglitazone, and liraglutide, we may finally be getting closer to the 'holy grail' of a diabetes drug that also has cardiovascular benefits. Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 11, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news

Diabetes drug pioglitazone could get personal: Neither panacea, nor peril
When I was in training, one of my beloved mentors declared, “I never use a drug until it’s been on the market for 20 years.” I was young enough then that I couldn’t fathom being a doctor for 20 years, let alone waiting two decades to use a new drug. As my career has progressed, I’ve seen many new drugs released to the market. Some of them are truly miraculous, bringing people longer, healthier, and more productive lives. Many of them have not withstood the test of time. More than a few have even been taken off the market. Even though the Food and Drug Administration diligently reviews each new...
Source: New Harvard Health Information - May 5, 2016 Category: Consumer Health News Authors: Lori Wiviott Tishler, MD, MPH Tags: Diabetes Drugs and Supplements pioglitazone thiazolidinediones Source Type: news

Pioglitazone Use and Risk of Bladder CancerPioglitazone Use and Risk of Bladder Cancer
The results of this large population based study indicate that pioglitazone is associated with an increased risk of bladder cancer. But is it drug specific, or a class effect? British Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 15, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Elevated bladder cancer risk with pioglitazone use
Use of the antidiabetic drug pioglitazone is linked to an increased risk of developing bladder cancer, with the risk rising with increasing duration of use and dose, say Canadian researchers. (Source: MedWire News)
Source: MedWire News - April 5, 2016 Category: Consumer Health News Tags: Oncology Source Type: news

FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer
[6-15-2011] The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 1, 2016 Category: Drugs & Pharmacology Source Type: news

Pioglitazone, Not Rosiglitazone, Again Tied to Bladder CancerPioglitazone, Not Rosiglitazone, Again Tied to Bladder Cancer
"Substantial and fairly consistent" evidence points to pioglitazone as associated with increased risk of bladder cancer, and this study strengthens and "confirms" that evidence, an expert says. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 1, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Diabetes drug linked to increased bladder cancer risk
A new study of 145,806 people who took pioglitazone compared to other oral diabetes drugs showed that it raises the risk of bladder cancer by 63%. Results were published in the BMJ. NHS Direct (Source: Society for Endocrinology)
Source: Society for Endocrinology - April 1, 2016 Category: Endocrinology Source Type: news

Diabetes drug linked with increased bladder cancer risk
The diabetes drug pioglitazone is associated with an increased risk of bladder cancer, according to a Canadian study. (Source: Nursing Times)
Source: Nursing Times - April 1, 2016 Category: Nursing Source Type: news

Diabetes drug taken by one million patients 'raises the risk of bladder cancer'
Pioglitazone helps to control blood sugar levels in patients with type 2 diabetes. It remains popular with doctors even though newer and better diabetes drugs exist because it is so cheap. (Source: the Mail online | Health)
Source: the Mail online | Health - March 31, 2016 Category: Consumer Health News Source Type: news

More Evidence Diabetes Drug Actos Raises Bladder Cancer Risk a Bit
But odds are small, and experts want it to remain on market, although newer drugs are available Source: HealthDay Related MedlinePlus Pages: Bladder Cancer, Diabetes Medicines, Drug Reactions (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 31, 2016 Category: Consumer Health News Source Type: news

Diabetes drug linked to increased bladder cancer risk
Conclusion It seems likely from this research that pioglitazone is linked to an increased risk of bladder cancer, although the overall chances of getting bladder cancer remain very low. While this type of research cannot prove that pioglitazone is the cause of the increased risk of bladder cancer, it is not easy to find a convincing alternative explanation for these results. Previous research has already shown unexpectedly higher levels of bladder cancer among people taking pioglitazone, although other studies had found no such link. However, the size and the care with which this new study was carried out makes it convinc...
Source: NHS News Feed - March 31, 2016 Category: Consumer Health News Tags: Cancer Diabetes Medication Source Type: news

More evidence diabetes drug Actos raises bladder cancer risk
Dennis Thompson, HealthDay News More evidence linking diabetes drug Actos to an increased risk of bladder cancer has surfaced in a new study that also finds the risk rises with increased use. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 31, 2016 Category: Consumer Health News Source Type: news

Diabetes drug ‘increases bladder cancer risk by 63%’, study suggests
Pioglitazone, a drug used to treat people with diabetes, could increase bladder cancer risk, suggests new research in the BMJ. Huffington Post (Source: Society for Endocrinology)
Source: Society for Endocrinology - March 31, 2016 Category: Endocrinology Source Type: news

More Evidence Diabetes Drug Actos Raises Bladder Cancer Risk a Bit
But odds are small, and experts want it to remain on market, although newer drugs are available (Source: U.S. News - Health)
Source: U.S. News - Health - March 31, 2016 Category: Consumer Health News Source Type: news